Is APAC Edging Closer to Clinical Application of Single-cell Tech?
BioSpectrum Asia|BioSpectrum Asia Oct 2023
Asia Pacific APAC) is expected to be a major contributor to the growth of single cell technology as the market is driven by factors such as the growing demand for personalised medicine, advancements in sequencing technologies, and the increasing use of single cell analysis in drug discovery. While Japan is currently the fastest-growing country in the APAC single-cell analysis market, Singapore, China, and India are showing significant progress in adopting this technology.
Anusha Ashwin
Is APAC Edging Closer to Clinical Application of Single-cell Tech?

A single cell contains multiple omics including genome, epigenome, transcriptome, and others. The completion of the Human Genome Project in 2003 was the beginning of deciphering the biological meaning of the three billion nucleotides in the human genome. Later, a key technological milestone was the release of several massively parallel DNA sequencing (next-generation sequencing) platforms in 2005 and 2007, which allowed for generating sequencing reads of billions of base pairs in a few days at a cost of less than $1,000. Moving on, the single-cell omics sequencing research started in 2009 when the single-cell RNA sequencing (scRNA-seq) assay was described.

In recent years, more and more single-cell technologies have been developed. A vast amount of single-cell omics data has been generated by large projects globally, such as the Human Cell Atlas, the Mouse Cell Atlas, the Mouse RNA Atlas, the Mouse ATAC Atlas, and the Plant Cell Atlas. Based on these single-cell big data, thousands of bioinformatics algorithms for quality control, clustering, cell-type annotation, developmental inference, cell-cell transition, cell-cell interaction, and spatial analysis are developed. Some of the most common single-cell technology methods include Single-cell RNA sequencing (scRNA-seq); Single-cell proteomics; Single-cell epigenomics; Single-cell imaging; and Single-cell electrophysiology.

Notably, the first successful demonstration of single cell RNA sequencing was published in 2009 by a team of researchers at the University of Washington led by Dr Jay Shendure and Dr Cole Trapnell. They used a method called Smart-seq to amplify and sequence the mRNA from individual mouse blastomeres (early-stage embryonic cells) and demonstrated that the technique could be used to profile gene expression in individual cells.

Bu hikaye BioSpectrum Asia dergisinin BioSpectrum Asia Oct 2023 sayısından alınmıştır.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.

Bu hikaye BioSpectrum Asia dergisinin BioSpectrum Asia Oct 2023 sayısından alınmıştır.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.

BIOSPECTRUM ASIA DERGISINDEN DAHA FAZLA HIKAYETümünü görüntüle
New South Wales government injects $5M for critical research to address Silicosis crisis
BioSpectrum Asia

New South Wales government injects $5M for critical research to address Silicosis crisis

The New South Wales (NSW) government in Australia has committed $5 million in critical funding for silicosis research and a patient support programme for individuals and their families navigating the health risks associated with exposure to silica dust.

time-read
1 min  |
BioSpectrum Asia May2024
Singapore approves new asthma indication for GSK's Trelegy Ellipta
BioSpectrum Asia

Singapore approves new asthma indication for GSK's Trelegy Ellipta

GSK Singapore has announced that the Health Sciences Authority (HSA) has approved a new indication and a new strength for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol 'FF/UMEC/VI') for the maintenance treatment of asthma in patients aged 18 years and older who are not adequately controlled with a combination of a long-acting beta2-agonist (LABA) and an inhaled corticosteroid (ICS).

time-read
1 min  |
BioSpectrum Asia May2024
What's APAC's Recipe of Success in CLINICAL TRIALS MARKET?
BioSpectrum Asia

What's APAC's Recipe of Success in CLINICAL TRIALS MARKET?

Asia-Pacific APAC) is emerging as one of the most promising and resilient markets for clinical trials. According to a report by Clinical Trials Arena, between 2017 and 2022, the region posted growth in clinical trials of around 10 per cent, outstripping growth in other major regions including the US, Europe and the rest of the world RoW). Asia’s growth far exceeded the overall average figure of 5.3 per cent per year. As of 2023, the number of trials reached 14,346 in APAC. Let's delve into the thriving clinical research landscape in the region and explore the trends driving its growth.

time-read
10+ dak  |
BioSpectrum Asia May2024
From Haematologic to Autoimmune DiseaseThe CAR-T Therapy Second Revolution
BioSpectrum Asia

From Haematologic to Autoimmune DiseaseThe CAR-T Therapy Second Revolution

Cell and gene therapies have revolutionised the field of medicine, offering new treatment options for patients with various diseases that, by type of disease or severity, were considered untreatable until a few years ago. Rapid technological advancements in genetic and biological engineering and improvements in the quality and standardisation of the manufacturing process are fostering a marked increase in clinical development of these advanced therapies, generally named cell and gene therapies CGT), and they are expected to receive more approvals in the near future.

time-read
5 dak  |
BioSpectrum Asia May2024
"Biotech startups still need support in terms of talent, and resources to bring their innovations to market"
BioSpectrum Asia

"Biotech startups still need support in terms of talent, and resources to bring their innovations to market"

Raymond Chow has recently stepped in as the Vice President, Asia Pacific at USheadquartered Cytiva, a global provider of technologies and services for biological therapies, formerly known as GE Healthcare Life Sciences.

time-read
5 dak  |
BioSpectrum Asia May2024
"We are exploring opportunities to collaborate with startups and incubators"
BioSpectrum Asia

"We are exploring opportunities to collaborate with startups and incubators"

Agilent Technologies, a global leader in analytical and clinical laboratory technologies, has named Padraig McDonnell CEO-elect and Chief Operating Officer (COO), succeeding current President and CEO Mike McMullen.

time-read
5 dak  |
BioSpectrum Asia May2024
"Australia offers a simple, supportive and robust regulatory process to initiate human trials efficiently"
BioSpectrum Asia

"Australia offers a simple, supportive and robust regulatory process to initiate human trials efficiently"

US-based Uvax Bio, LLC, a spin-off vaccine company from Scripps Research, employs proprietary 1c-SApNP platform technology invented by Dr Jiang Zhu of Scripps Research to develop and commercialise prophylactic vaccines for challenging infectious diseases.

time-read
2 dak  |
BioSpectrum Asia May2024
"Regulatory encouragement of advanced tech, including AI will accelerate clinical trials in APAC"
BioSpectrum Asia

"Regulatory encouragement of advanced tech, including AI will accelerate clinical trials in APAC"

Lokavant Holdings, a US-based clinical trial intelligence technology company provides clinical trial intelligence that enables study teams to make data-driven decisions, as well as risk-based quality management and monitoring services to pharmaceutical companies and contract research organisations (CROs).

time-read
2 dak  |
BioSpectrum Asia May2024
What Are the Main Challenges of Modern Clinical Trials?
BioSpectrum Asia

What Are the Main Challenges of Modern Clinical Trials?

With a cumulative total of almost 478,000 globally registered trials from the year 2000 to 2023, and growing at around 10 per cent a year in the last five years, the pharmaceutical industry continues to invest in clinical trials as the gold-standard test of therapeutic safety and efficacy. In addition, as the world’s economies and populations move in new directions, the share of non-US trials has reached 54 per cent, a trend that is likely to continue, driven by demographics and epidemiology. As the pace accelerates, trial managers and clinicians face a significant challenge: the explosive growth of data volumes. To succeed in the future, clinical trials need to increase efficiency and better utilise clinical trial data to support informed clinical and operational decision-making.

time-read
3 dak  |
BioSpectrum Asia May2024
How APAC Has Turned into Clinical Trial Behemoth
BioSpectrum Asia

How APAC Has Turned into Clinical Trial Behemoth

From being a consistent participant in clinical trial conduct worldwide, the APAC has emerged as a major power. A number of causes, including the region's thriving drug development innovation and the ongoing presence of international pharmaceutical corporations conducting multiregional studies, are driving this growth.

time-read
3 dak  |
BioSpectrum Asia May2024